1. Analyst View
2. Research Methodology
3. Cancer Statistics by Demographics
3.1 Prevalence, Incidences, and Mortality (2009-2017)
3.2 Leading States by Incidence
3.3 Leading Cancers by Incidence
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Age-Group
4. US Personalized Cancer WGS Potential Market
5. US Personalized Cancer WGS: Current and Future Market Analysis
6. Regulatory Insights
6.1 Clinical Laboratory Improvement Amendments (CLIA) Accreditation
6.2 CAP Accreditation
7. Market Constraints
8. Competitive Assessment
8.1 Illumina
8.1.1 Business Overview
8.1.2 Strengths and Weaknesses
8.2 Complete Genomics
8.2.1 Business Overview
8.2.2 Strengths and Weaknesses
8.3 Beckman Coulter Genomics
8.3.1 Business Overview
8.3.2 Strengths and Weaknesses
8.4 Expression Analysis
8.4.1 Business Overview
8.4.2 Strengths and Weaknesses
8.5 EdgeBio
8.5.1 Business Overview
8.5.2 Strengths and Weaknesses
8.6 Foundation Medicine
8.6.1 Business Overview
8.6.2 Strengths and Weaknesses
8.7 SeqWright
8.7.1 Business Overview
8.7.2 Strengths and Weaknesses
8.8 Ambry Genetics
8.8.1 Business Overview
8.8.2 Strengths and Weaknesses
8.9 BGI Americas Corporation
8.9.1 Business Overview
8.9.2 Strengths and Weaknesses
8.10 Cofactor Genomics
8.10.1 Business Overview
8.10.2 Strengths and Weaknesses
